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Breastmilk, the white liquid produced by the mammary glands, is 
the primary source of nutrition for infants before they are able to 
digest other types of food. Modified cow’s milk formulas are the 
commonest breastmilk replacement formula, but are not always tol­
erated by infants with lactose intolerance or cow’s milk protein allergy 
(CMPA). CMPA is an immune­mediated hypersensitivity reaction to 
cow’s milk protein,[1] which may be IgE mediated (presenting with 
urticaria, angio­oedema, and respiratory, abdominal and cardiac 
signs, and ranging from mild to anaphylactic reactions), or non­
IgE mediated (presenting with delayed­type reactions, mainly in 
the gastrointestinal tract). The prevalence of CMPA is estimated 
at 2 ­ 4% worldwide, and preliminary data from the South African 
Food sensitisation and Food Allergy (SAFFA) study show a 6.4% 
prevalence of sensitisation and a 0.2% prevalence of challenge­proven 
CMPA in 1 ­ 3­year­old unselected urban infants.[2]
Cow’s milk comprises casein and whey allergenic proteins. The 
casein allergens (collectively known as Bos d 8) comprise four 
different proteins (alpha­S1, alpha­S2, beta and kappa casein). The 
most important whey allergens include beta­lactoglobulin (Bos d 
5, the most abundant cow’s milk whey protein, which occurs in the 
milk of many other species but is not present in human milk) and 
alpha­lactalbumin (Bos d 4). Bovine serum albumin (Bos d 6) and 
bovine immunoglobins (Bos d 7) are less common allergens. The 
most common cow’s milk antigens are intact proteins of a molecular 
weight between 14 and 150 kDa.[3] Cow’s milk casein has a molecular 
weight of 19 ­ 25.2 kDa. Beta­lactoglobulin has a molecular weight of 
18.3 kDa, α­lactalbumin 14.2 kDa, bovine serum albumin 66.3 kDa 
and bovine immunoglobin G 150 kDa.
Cow’s milk formulas are categorised according to the degree of hydro­
lysis into intact milk protein formulas, partially hydrolysed formulas 
(PHFs) or extensively hydrolysed formulas (EHFs). In addition, amino 
acid­based formulas (AAFs) manufactured from hydrolysis of non­
milk proteins or by combining individual amino acids are available. 
The nature of the formula may add additional indications to its use 
apart from its nutritional role, such as for dietary management as a 
replacement formula in children with established CMPA.
The term ‘hypoallergenic formulas’ was first used by Kleinman 
et al.[4] to refer to formulas that are tolerated by 90% of subjects 
with proven cow’s milk allergy with a 95% confidence interval, 
and are therefore used for the treatment of cow’s milk allergy. 
This definition was subsequently adopted by the World Allergy 
Organization (WAO).[5]
A statement of the European Society for Pediatric Allergology and 
Clinical Immunology[6] stated in 1998 that infant formulas with a 
content of immunoreactive protein of <1% of total nitrogen (which 
translates into the majority of peptides <1.5 kDa[7]) may be labelled 
as having ‘reduced allergenicity’. In 2000, the American Academy of 
Pediatrics defined an extensively hydrolysed formula as a formula 
containing only peptides that have a molecular weight of <3 kDa.[8] 
The guideline states that formulas with ‘most of the nitrogen in the 
form of free amino acids and peptides <1.5 kD have been subjected to 
extensive clinical testing and meet the standard for hypoallergenicity’. 
In 2008, the American Academy of Pediatrics[9] defined partially 
hydrolysed formulas as those that contain oligopeptides with a 
molecular weight generally <5 kDa, extensively hydrolysed formulas 
as containing only peptides that have a molecular weight <3 kDa and 
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free amino acid­based formulas as peptide­free mixtures of essential 
and non­essential amino acids. It is possible that individual amino 
acids can polymerise and form simple (usually di­ or tri­) peptides.
Cross­linking of Fcε receptor­bound IgE requires that an allergen 
contains at least two IgE­binding epitopes with a size of at least 
15 amino acids. This implies that proteins with a size of <3 kDa are 
incapable of causing an allergic reaction.[10] PHFs are not considered 
to be hypoallergenic according to Kleinman et al.’s[4] definition; 
however, many EHFs have been proven to be hypoallergenic and all 
AAFs are hypoallergenic.
Current milk labelling practices are, however, confusing and 
contested. For example, many partially hydrolysed feeds are labelled 
as ‘HA’ and are referred to widely as ‘hypoallergenic’ because there 
has been some modification of their milk protein content by partial 
hydrolysis. Such partially hydrolysed feeds may have some efficacy 
in prevention of CMPA in high­risk subjects whose mothers are 
unable to breastfeed, but they are not suitable for subjects with 
confirmed CMPA, as they do not conform to the WAO definition of 
hypoallergenicity.
There have recently been changes to infant formula­labelling legis­
lation in South Africa (SA). South African Department of Health 
Government Notice 35941 on 6 December 2012 (no. R991) [11] legis­
lated that mandatory statements on the labels of infant formula 
for special dietary management of infants with specific medical 
conditions replace claims of formula type or allergenicity (e.g. 
extensively or partially hydrolysed, allergen free, amino acid 
or hypoallergenic). Statements allowed include ‘for the dietary 
management of infants with cow’s milk allergy’ or ‘for the dietary 
management of infants with cow’s milk allergy, multiple food protein 
allergies’. The criteria by which such labelling is applied are not clear.
South African Department of Health Government Notice 32975 on 
1 March 2010 (no. R146)[12] is concerned with hypoallergenic, non­
allergenic or allergen­free claims. The notice states that no claim shall 
be made that a foodstuff is hypoallergenic, non­allergenic or free of a 
common or uncommon allergen unless it is modified so as to reduce 
the endogenous antigens in such a way that it is not possible to detect 
the presence of any possible allergen with testing suitable for the 
specific allergen, or it has been tested to confirm the absence of such 
antigens using suitable testing.
The definition of what testing is suitable, which antigens should 
be tested for and in what form (e.g. size, degree of hydrolysis) is not 
covered by the legislation. With regard to infant formulas, candidates 
for testing include the native allergens themselves as well as the 
products of hydrolysis.
Objectives
To evaluate the residual allergen, protein, peptide and amino­acid 
content of AAFs and EHFs available in SA. This included:
• Testing for milk protein allergens (whole milk, β­lactoglobulin, 
casein, α­lactalbumin) in AAFs and EHFs and comparing these 
with whole cow’s milk and human breastmilk
• Testing for egg albumin, peanut and soy allergens in AAFs, EHFs, 
whole cow’s milk and human breastmilk
• Testing for protein (peptides and amino acids) and the range in 
protein sizes in AAFs and EHFs and comparing these with whole 
cow’s milk and human breastmilk.
Methods
Institutional review and ethical approval were sought and obtained 
(Human Research Ethics Committee, University of Cape Town, ref. 
no. 270/2014). Manufacturers of all companies marketing AAFs 
or EHFs in SA were notified of the research and permission was 
requested to identify their products by name. Where companies 
did not give permission for their products to be identified by name, 
they were referred to as the type of formula followed by a numeral 
if more than one of the same type of formula remained un­named 
(Table 1).
Where available, feeds were purchased from local pharmacies. 
Aminomed and Comidagen Plus (Nutr­e­Volution) were obtained 
directly from the manufacturer as they are sold via web­based 
ordering, and Neomino (Cipla) was obtained directly from the 
manufacturer as the feed had not yet been commercially launched.
The formulas were reconstituted according to the manufacturer’s 
specifications under sterile conditions with sterile water ensuring 
no contamination, then aliquoted and frozen at –20oC until thawed 
for specific analysis. Chemicals were of reagent grade. Deionised 
water was used for solutions. The samples were weighed on the 
same electronic balance and analyses were carried out in solutions 
according to the manufacturer’s instructions, but were scaled down 
to practical volumes for use in the laboratory.
Allergen content
Formulas were tested in duplicate by enzyme­linked immunosor­
bent assay (ELISA) for whole­milk protein (α­, β­ and κ­caseins, 
β­lactoglobulin), and individual β­lactoglobulin, casein, egg albumin, 
peanut and soy proteins using Ridascreen Fast test kits (R­Biopharm 
AG, Germany) and for α­lactalbumin (Bethyl Laboratories, USA).
These ELISA test kits were used for the quantitative analysis of 
residual milk allergen content in AAFs and EHFs, and tests were 
performed according to the manufacturer’s protocol. Whole cow’s 
milk and human breastmilk served as positive and negative controls, 
respectively. In addition, all samples were tested for the presence of 
soy, peanut and egg allergens.
Protein concentration and sizes
Conventional spectrophotometric protein assays are unreliable for 
small proteins and peptides, and two approaches were therefore used 
to describe these molecules by size.
• Coomassie Blue staining of proteins separated by sodium dode-
cyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Each 
sample was reduced and denatured and underwent separation 
of amino acids, peptides and proteins in a 5 ­ 20% gradient 
poly acrylamide gel.[13] Poly acrylamide gel was prepared in the 
laboratory in a Mini Protean II apparatus (Biorad, USA) according 
to Laemmli. [14] Before application, 3 μL of the sample were heated 
with 1% SDS and mercaptoethanol. Bromphenol blue was used with 
sucrose to load the sample. After running at 130 V until the blue dye 
approached the end of the gel, the gel was stained in Coomassie Blue 
solution and destained in methanol­acetic acid.
• Size-exclusion chromatography for amino acids and peptides. 
The reconstituted formula was filtered (0.45 microns) and analysed 
isocratically on an Agilent 1260 Infinity high­performance liquid 
chromatography (HPLC) system (Agilent, USA) that detected the 
absorption at selected wavelengths by diode array. The elution 
profiles were analysed for area under the curve (AUC) using the 
Masshunter software acquired with the machine. An Agilent 
SEC3 size exclusion column (Agilent, USA) was used with a 
flow rate of 0.35 mL/min using phosphate­buffered saline. This 
separates molecules between 100 kDa and 0.1 kDa. Calibration 
was carried out with selected amino acids and proteins. Adequate 
post­time was used to ensure no carry­over. HPLC employs a 
flow of molecules in solution through porous material that retards 
the progress of smaller molecules more than large molecules 
because the former venture into smaller spaces, increasing their 
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travel distance relative to the large molecules that flow through 
the column with practically no delay. The molecular size markers 
were gamma­globulin (150 kDa) at the void volume, albumin 
(66 kDa), oxytocin (1.00 kDa), tryptophan (0.204 kDa) and glycine 
(0.075 kDa).
Results
Allergen content
All AAF and EHF samples were negative for all milk allergens tested, 
with values below the detection limit of the assays (milk 2.5 mg/kg, 
α­lactalbumin 0.78 mg/kg, β­lactoglobulin and casein 0.5 mg/kg). 
The cow’s milk sample, on the other hand, was positive for all milk 
allergens with values above the upper detection range of the assay 
(milk 67.5 mg/kg, α­lactalbumin 50 mg/kg, β­lactoglobulin and 
casein 13.5 mg/kg), confirming correct performance of the tests. As 
expected, no cow’s milk allergens were detected in human breastmilk. 
Furthermore, all samples tested negative for soy, peanut and egg 
allergens below the detection limit of the assays (peanut and soy 
2.5 mg/kg, egg albumin 0.5 mg/kg).
Protein electrophoresis
After electrophoresis, staining with Coomassie Blue did not reveal 
any protein in the lanes containing reconstituted formulas. Proteins 
stained readily in cow’s milk (lanes 10 and 12) as well as human milk 
(lane 11) (Fig. 1). Coomassie Blue stains proteins unreliably below 3 
kDA and has a limit of detection at 0.1 μg or even less. No protein 
was visible in any of the formula samples tested above the limit of 
detection of Coomassie Blue. The protein profiles differed between 
the cow’s and human milk.
An attempt was made to detect small peptides and amino acids in a 
similar gel that was modified to 15% acrylamide to favour separation 
of smaller peptides, by derivatisation of carboxylic acid moieties with 
the fluorescent dye PDAM (1­pyrenyldiazomethane). This readily 
demonstrated glycine and tryptophan and conjugated material of 
identical size in the formulas, but larger peptides were not seen. In 
contrast, the cow’s milk and breastmilk lanes lacked fluorescence in 
the range of single amino acids and small peptides, but there was faint 
fluorescence from the smallest size of protein seen in the Coomassie­
stained gels as well as in larger proteins (data not shown).
HPLC with size exclusion
HPLC with diode array detection of eluting compounds from a size 
exclusion column was used to discriminate molecules from amino 
acids through oligopeptides to proteins.
The area of interest was determined by extrapolation from the 
markers: 13 minutes representing 3.02 kDa, 14 minutes 1.55 kDa 
and 16 minutes 0.40 kDa. The peaks for the largest amino acid 
(tryptophan, 0.204 kDa) and the smallest (glycine, 0.075 kDa) were 
at 16.3 and 16.9 minutes, respectively.
The HPLC analysis covers the range of peptides below a molecular 
size of 3 kDa that could be missed by the SDS­PAGE analysis. The 
HPLC analysis of very small molecules for sizes up to ~0.4 kDa could 
include the largest polymer of pentameric glycine and the simplest 
dimer could be one with tryptophan. Very small (oligo­) peptides can 
be considered to be in the size range of 0.4 ­ 1.5 kDa. The polymer 
with the largest number of amino acids in this range could be the 
triscidecamer of glycine and the lowest number of amino acids could 
be the pentamer of tryptophan. The larger peptides from 1.5 to 3 kDa 
could be a 40­mer of glycine to a 15­mer of tryptophan. The detection 
of molecules by ultraviolet absorption favours amino acids, but may 
include other compounds.
The elution profiles of the formula samples contain material 
absorbing at molecular mass equivalents >3 kDa. The SDS­PAGE 
analysis indicates that these absorbing substances are not proteins.
The overlay of all the elution profiles (Fig. 2) illustrates that the 
region between 3 kDa and 0.4 kDa is relatively clear of molecules 
absorbing at 214 nm, with very similar patterns in the single amino­
acid region between 16 and 18 minutes, indicated by tryptophan 
Table 1. AAFs and EHFs tested
Product Intended age Description
AAFs
Aminomed (Nutr­e­Volution) <1 year Free amino­acid formula 
Comidagen Plus (Nutr­e­Volution) >1 year Free amino­acid formula
Neocate LCP (Nutricia) <1 year Free amino­acid formula 
Neocate Advance (Nutricia) >1 year Free amino­acid formula 
Neomino (Cipla) <1 year Free amino­acid formula
EHFs
Alfare (Nestlé) <1 year Hydrolysed whey 
Pepticate (Nutricia) <1 year Hydrolysed whey 
Casein EHF 1 <1 year Hydrolysed casein 
Similac Alimentum (Abbott) <1 year Hydrolysed casein 
AAFs = amino acid­based formulas; EHFs = extensively hydrolysed formulas.
Fig. 1. Milk formula electrophoresis. (Lanes: 1 Alfare, 2 Allernova, 3 Pepti­
cate, 4 Similac Alimentum, 5 Aminomed, 6 Comidagen Plus, 7 Neocate 
Advance, 8 Neocate LCP, 9 Neomino, 10 full­cream cow’s milk, 11 breast­
milk, 12 fat­free milk. M1 molecular mass markers (small to large): 10, 15, 
25, 35, 40, 55, 70, 100, 130, 170 kDa; M2 molecular mass markers (small to 
large): 14.3, 21.5, 30, 46, 69, 97.4, 200 kDa.)
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and glycine on the control elutions. The cow’s milk and breastmilk 
samples contained no material at these low­molecular­weight ranges. 
This indicates that molecules larger than 3 kDa were mostly absent in 
all formula samples tested.
The elution profiles were analysed for AUC in various segments 
representing 3 ­ 1.5 kDa and 1.5 ­ 0.4 kDa, and the ratios were compared 
for these segments and the whole AUC for the region of <3 kDa.
Although little difference was apparent in the molecular mass 
range between amino acids and 3 kDa, the AUC was analysed to 
crudely examine for differences between the two formula groups. 
The different formulations varied approximately four­fold in the 3.0 ­ 
1.5 kDa peptide range, as well as in the 1.5 ­ 0.4 kDa peptide range, 
whereas the variation was seven­fold in the <0.4 kDa (amino­acid) 
range. Comparison of the EHF group with the AAF group indicated 
that the EHF preparations had a trend towards a greater AUC for 
the 0.4 ­ 1.5 kDa size range than the AAF group (mean (standard 
deviation (SD)) 1 383 (578) v. 687 (346); p=0.064). In the <0.4 kDa 
amino­acid region, the AAF group had a trend towards a higher AUC 
than the EHF group (mean 8 453 (3 226) v. 4 326 (2 442); p=0.064).
The proportion of amino acids <0.4 kDa in relation to the total 
range (peptides plus amino acids) was significantly higher in the 
AAF group than in the EHF group (mean (SD) 0.850 (0.062) v. 0.631 
(0.126); p=0.032). The EHF group also had a higher proportion 
of (presumed peptide) molecules >0.4 kDa compared with amino 
acids and small oligopeptides (<0.4 kDa) than the AAF group 
(mean 0.630 (0.295) v. 0.182 (0.089), respectively; p=0.032). Taken 
together, these findings suggest that EHFs may have more small 
oligopeptides than AAFs. According to these indirect criteria, >50% 
of the EHF molecules were <0.4 kDa, compared with >75% of the 
AAF formulations.
Interestingly, there was no demonstrable material between 1.5 
and 0.4 kDa in cow’s milk and human breastmilk, but the latter had 
demonstrable material between 0.4 and 3 kDa (data not shown).
Discussion
It is extremely important that feeds for the dietary management of 
individuals with CMPA are free of residual allergenicity. Even trace 
amounts of native protein can cause significant reactions.[15]
The samples analysed in this study were randomly selected and 
are likely to be representative of the formulas in general. Since the 
formulas are manufactured according to set methods and with good 
quality control, it is unlikely that there will be significant differences 
from time to time.
All samples of AAFs and EHFs tested negative for all milk, soy, 
peanut and egg allergens in quantitative allergen­specific ELISA tests. 
This supports the conclusion that no protein antigens of a size large 
enough to bind to antibodies were present in the tested formulas.
Polyacrylamide gel analysis showed that none of the formulas 
tested contained detectable protein >3 kDa, in contrast to the large 
amounts and variety of proteins in the cow’s milk and breastmilk. 
The formulas lacked detectable large proteins and can therefore 
appropriately be termed protein­free, although technically small 
amounts of oligopeptides may be present.
The formulas vary significantly in the range of interest in molecular 
size, as described in Table 2. The detection of these molecules is not 
specific to amino acids, but was used to estimate differences in the 
low concentrations between amino acids and small oligopeptides. The 
AUC values for the molecular sizes between 3 kDa and 0.4 kDa are 
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Fig. 2. Milk high­performance liquid chromatography peptide profile. 
(*Time after injection at which the peak was noted.)
Table 2. AUC for compounds <3 kDa, and their ratios for selected regions detected by spectrophotometry
Feed type Sample 
3 - 1.5 kDa 
(peptides)
1.5 - 0.4 kDa 
(peptides)
0.4 - 0.1 kDa 
(AAs)
AAs divided by 
(peptides + AAs) Peptides/AAs
EHF Alfare 1 267 1 969 5 870 0.645 0.551
EHF EHF 1 503 1 783 2 694 0.541 0.849
EHF Pepticate 789 813 1 836 0.534 0.873
EHF Alimentum 722 968 6 904 0.803 0.245
AAF Aminomed 285 1 304 7 785 0.830 0.204
AAF Comidagen Plus 953 496 12 664 0.897 0.114
AAF Neocate LCP 338 514 8 682 0.911 0.098
AAF Neocate Advance 1 048 563 9 421 0.854 0.171
AAF Neomino 638 558 3 715 0.756 0.322
Mean 727 996 6 619 0.752 0.381
SD 327 565 3 489 0.145 0.304
AUC = area under the curve; AAs = amino acids; EHF = extensively hydrolysed formula; AAF = amino acid­based formula; SD = standard deviation.
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low relative to the amino­acid range in all samples. There is a trend 
towards more single amino­acid molecules in the AAFs than in the 
EHFs and for more oligopeptides in the EHFs than in the AAFs.
AAFs had a significantly higher proportion of amino acids in 
relation to the total range (peptides plus amino acids) than EHFs. 
Conversely, the EHFs had a higher proportion of oligopeptide 
molecules compared with amino acids than the AAFs. More than 
50% of the EH molecules were <0.4 kDa compared with >75% in 
the AAFs.
The clinical significance of the molecules between 0.4 and 3 kDa 
is unknown. While it is possible that they may be immunogenic, 
they are subject to further digestion and modification in the body. 
It is theoretically possible to examine these molecules as antigens by 
performing reactions with plasma from patients suspected of allergy. 
It is unlikely that there is merit in analysing the species of oligomers 
of amino acids in the range of 3 ­ 0.1 kDa, unless a specific compound 
is thought to be particularly immunogenic. It is also possible that 
oxidatively modified amino acids could be present in the formulas. 
Such modification could happen during preparation or storage.
These data support the opinions expressed by the international 
Diagnosis and Rationale for Action against Cow’s Milk Allergy[16] 
food allergy guidelines and the recent South African consensus 
statement[1] that extensively hydrolysed and amino acid formulas are 
suitable for the dietary management of cow’s milk protein allergy. It 
is therefore appropriate that these formulas be labelled accordingly, in 
line with current legislation.
Unintended consumption of allergenic proteins can occur despite 
excellent labelling, for example due to an allergen’s unlabelled 
inclusion in a food or cross­contamination during processing or after 
manufacture.[15] Cross­contamination can be detected with ELISA 
testing to prove the presence of unintended allergens in both liquid 
and solid foodstuffs.
Conclusions
All AAFs and EHFs currently available in SA were found to 
be similar in composition, with an absence of proteins and a 
prominence of very small molecules. They have no residual 
allergenicity on ELISA testing for the native cow’s milk protein and 
major allergenic components. Protein chains, where present, are of 
sufficiently small length to make it extremely likely that they will 
comply with the definition of hypoallergenicity as being tolerated 
by 90% of proven sufferers from cow’s milk allergy, and they should 
therefore be labelled as suitable for the dietary management of 
subjects with cow’s milk protein allergy.
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